Soligenix (SNGX)
NASDAQ:SNGX
Holding SNGX?
Track your performance easily

Soligenix (SNGX) Stock Price & Analysis

642 Followers

SNGX Stock Chart & Stats


Financials

Annual

Ownership Overview

20.33%0.14%<0.01%79.39%
20.33%
Insiders
<0.01% Other Institutional Investors
79.39% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

SNGX FAQ

What was Soligenix’s price range in the past 12 months?
Soligenix lowest stock price was $1.83 and its highest was $32.01 in the past 12 months.
    What is Soligenix’s market cap?
    Currently, no data Available
    When is Soligenix’s upcoming earnings report date?
    Soligenix’s upcoming earnings report date is Nov 13, 2024 which is in 3 days.
      How were Soligenix’s earnings last quarter?
      Soligenix released its earnings results on Aug 09, 2024. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.775 by $0.465.
        Is Soligenix overvalued?
        According to Wall Street analysts Soligenix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Soligenix pay dividends?
          Soligenix does not currently pay dividends.
          What is Soligenix’s EPS estimate?
          Soligenix’s EPS estimate is -$1.39.
            How many shares outstanding does Soligenix have?
            Soligenix has 2,280,421 shares outstanding.
              What happened to Soligenix’s price movement after its last earnings report?
              Soligenix reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.775. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Soligenix?
                Currently, no hedge funds are holding shares in SNGX
                ---

                Soligenix Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Soligenix

                Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Bio-Path Holdings
                Zomedica Pharmaceuticals
                Advaxis
                Akari Therapeutics
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis